World Journal of Surgery

, Volume 34, Issue 6, pp 1222–1231 | Cite as

Three Distinctly Different Kinds of Papillary Thyroid Microcarcinoma should be Recognized: Our Treatment Strategies and Outcomes

  • Iwao Sugitani
  • Kazuhisa Toda
  • Keiko Yamada
  • Noriko Yamamoto
  • Motoko Ikenaga
  • Yoshihide Fujimoto



Papillary microcarcinoma (PMC) of the thyroid generally follows a benign clinical course. However, treatment strategies remain controversial. According to our previous retrospective review of 178 patients with PMC who underwent surgery between 1976 and 1993, the most significant risk factors affecting cancer-specific survival were clinical symptoms at presentation due to invasion or metastasis. Distant metastasis and cancer-specific death were never seen postoperatively for 148 cases (83%) of asymptomatic PMC without clinically apparent (≥1 cm) lymph node metastasis or recurrent nerve palsy. Based on these results, we identified three biologically different types of PMC that should be treated differently. Type I comprises incidentally detected PMC without any symptoms, which is harmless and the lowest-risk cancer. Conservative follow-up with ultrasonography every 6 or 12 months is feasible. Type II involves the early stage of the usual low-risk papillary carcinoma. This can be treated by lobectomy when increasing size is noted during conservative follow-up. Type III comprises clinically symptomatic PMC, representing a high-risk cancer. Immediate wider resection followed by radioiodine treatment and suppression of thyroid-stimulating hormone is recommended.


Since 1995, we have been conducting a prospective clinical trial of nonsurgical observation for asymptomatic PMC. As of 2008, 230 of 244 candidates (94%) have decided to accept this policy, whereas 56 patients underwent surgery for symptomatic PMC between 1976 and 2006.


Nonsurgical observation for a mean of 5 (range, 1–17) years for 300 lesions of asymptomatic PMC revealed that 22 (7%) had increased in size, 269 (90%) were unchanged, and 9 (3%) had decreased. No patients developed extrathyroidal invasion or distant metastasis. Three patients (1%) who developed apparent lymph node metastasis and nine patients (4%) in whom tumor increased in size eventually received surgery after 1–12 years of follow-up. No recurrences have been identified postoperatively. Conversely, 10-year cause-specific survival for symptomatic PMC was 80%. Multivariate analysis identified extrathyroidal invasion, large lymph node metastasis (≥2 cm), and poorly differentiated component as significantly related to adverse outcomes.


Nonsurgical observation seems to represent an attractive alternative to surgery for asymptomatic PMC. Almost 95% of asymptomatic PMC patients are type I, and another 5% are type II and can be treated with conservative surgery. A small number of PMCs with bulky lymph node metastasis or extrathyroidal invasion are high-risk type III and require aggressive treatment.


Thyroid Cancer Papillary Thyroid Carcinoma Recurrent Laryngeal Nerve Total Thyroidectomy Cancer Institute Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported in part by the Foundation for the Promotion of Cancer Research in Japan.


  1. 1.
    Hedinger CE, Williams ED, Sobin LH (1988) Histological typing of thyroid tumours. The WHO international histological classification of tumours, 2nd edn. Springer-Verlag, BerlinGoogle Scholar
  2. 2.
    Takahashi S (1969) Clinicopathological studies of latent carcinoma of the thyroid [in Japanese]. Nippon Naibunpi Gakkai Zasshi (Folia Endocrinol Japon) 45:65–79Google Scholar
  3. 3.
    Sampson RJ, Key CR, Buncher CR et al (1970) Papillary carcinoma of the thyroid gland: sizes of 525 tumors found at autopsy in Hiroshima and Nagasaki. Cancer 25:1391–1393CrossRefPubMedGoogle Scholar
  4. 4.
    Sampson RJ, Woolner LB, Bahn RC et al (1974) Occult thyroid carcinoma in Olmsted country, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. Cancer 34:2072–2076CrossRefPubMedGoogle Scholar
  5. 5.
    Fukunaga FH, Yatani R (1975) Geographic pathology of occult thyroid carcinomas. Cancer 36:1095–1099CrossRefPubMedGoogle Scholar
  6. 6.
    Bondeson L, Ljungberg O (1981) Occult thyroid carcinoma at autopsy in Malmö, Sweden. Cancer 47:319–323CrossRefPubMedGoogle Scholar
  7. 7.
    Olen E, Klinck GH (1966) Hyperthyroidism and thyroid cancer. Arch Pathol 81:531–535PubMedGoogle Scholar
  8. 8.
    Carlini M, Giovannini C, Mercadante E et al (2006) Incidental thyroid microcarcinoma in benign thyroid disease: incidence in a total of 100 consecutive thyroidectomies [in Italian]. Chir Ital 58:441–447PubMedGoogle Scholar
  9. 9.
    Noguchi S, Yamashita H, Uchino S et al (2008) Papillary microcarcinoma. World J Surg 32:747–753CrossRefPubMedGoogle Scholar
  10. 10.
    Hay ID, Hutchinson ME, Gonzalez-Losada T et al (2008) Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144:980–988CrossRefPubMedGoogle Scholar
  11. 11.
    Allo MD, Christianson W, Koivunen D (1988) Not all “occult” papillary carcinomas are “minimal”. Surgery 104:971–976PubMedGoogle Scholar
  12. 12.
    Sanders LE, Rossi RL (1995) Occult well differentiated thyroid carcinoma presenting as cervical node disease. World J Surg 19:642–647CrossRefPubMedGoogle Scholar
  13. 13.
    Sugitani I, Yanagisawa A, Shimizu A et al (1998) Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World J Surg 22:731–737CrossRefPubMedGoogle Scholar
  14. 14.
    Cobin RH, Gharib H, Bergman DA et al (2001) AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 7:202–220PubMedGoogle Scholar
  15. 15.
    AACE/AME Task Force on Thyroid Nodules (2006) American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 12:63–102Google Scholar
  16. 16.
    British Thyroid Association, Royal College of Physicians (2007) Guidelines for the management of thyroid cancer, 2nd edn.
  17. 17.
    The American Thyroid Association Guideline Taskforce (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109–142CrossRefGoogle Scholar
  18. 18.
    Sugitani I, Fujimoto Y (1999) Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 46:209–216CrossRefPubMedGoogle Scholar
  19. 19.
    Sugitani I, Kasai N, Fujimoto Y et al (2004) A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135:139–148CrossRefPubMedGoogle Scholar
  20. 20.
    Sugitani I, Fujimoto Y, Yamamoto N (2008) Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery 143:35–42CrossRefPubMedGoogle Scholar
  21. 21.
    Sugitani I, Fujimoto Y, Yamada K et al (2008) Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. World J Surg 32:2494–2502CrossRefPubMedGoogle Scholar
  22. 22.
    Sugitani I, Fujimoto Y (2009) Management of low-risk papillary thyroid carcinoma: unique conventional policy in Japan and our efforts to improve the level of evidence. Surg Today (in press)Google Scholar
  23. 23.
    Medical Professionalism Project (2002) Medical professionalism in the new millennium: a physicians’ charter. Lancet 359:520–522CrossRefGoogle Scholar
  24. 24.
    Wada N, Duh QY, Sugino K et al (2003) Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 237:399–407CrossRefPubMedGoogle Scholar
  25. 25.
    Ito Y, Miyauchi A (2007) A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Nat Clin Pract Endocrinol Metab 3:240–248CrossRefPubMedGoogle Scholar
  26. 26.
    Davies L, Gilbert Welch H (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167CrossRefPubMedGoogle Scholar
  27. 27.
    Roti E, degli Uberti EC, Bondanelli M et al (2008) Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 159:659–673CrossRefPubMedGoogle Scholar
  28. 28.
    Chow SM, Law SCK, Chan JKC et al (2003) Papillary microcarcinoma of the thyroid: prognostic significance of lymph node metastasis and multifocality. Cancer 98:31–40CrossRefPubMedGoogle Scholar
  29. 29.
    Roti E, Rossi R, Trasforini G et al (2006) Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 91:2171–2178CrossRefPubMedGoogle Scholar
  30. 30.
    Cappelli C, Castellano M, Braga M et al (2007) Aggressiveness and outcome of papillary thyroid carcinoma versus microcarcinoma: a mono-institutional experience. J Surg Oncol 95:555–560CrossRefPubMedGoogle Scholar
  31. 31.
    Van den Bruel A, Moreno-Reyes R, Bex M et al (2008) Is the management of thyroid nodules and differentiated thyroid cancer in accordance with recent consensus guidelines? Results of a national survey. Clin Endocrinol 68:599–604CrossRefGoogle Scholar
  32. 32.
    Mazzaferri EL (2007) Management of low-risk differentiated thyroid cancer. Endocr Pract 5:498–512Google Scholar
  33. 33.
    Cady B (1998) Presidential address: beyond risk groups: a new look at differentiated thyroid cancer. Surgery 124:947–957PubMedGoogle Scholar
  34. 34.
    Pelizzo MR, Boschin LM, Toniato A et al (2006) Papillary thyroid microcarcinoma: prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol 32:1144–1148CrossRefPubMedGoogle Scholar
  35. 35.
    Rouxel A, Hejblum G, Bernier MO et al (2004) Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 89:5362–5368CrossRefPubMedGoogle Scholar
  36. 36.
    Ito Y, Tomoda C, Uruno T et al (2004) Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg 28:1115–1121CrossRefPubMedGoogle Scholar
  37. 37.
    Ito Y, Tomoda C, Uruno T et al (2004) Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg 28:498–501CrossRefPubMedGoogle Scholar
  38. 38.
    Ito Y, Uruno T, Nakano K et al (2003) An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381–387CrossRefPubMedGoogle Scholar
  39. 39.
    Cady B, Rossi R (1988) An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery 104:947–953PubMedGoogle Scholar
  40. 40.
    Hay ID, Grant CS, Taylor WF et al (1987) Ipsilateral lobectomy versus bilateral lober resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088–1095PubMedGoogle Scholar
  41. 41.
    Hay ID, Bergstralh EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1058PubMedGoogle Scholar
  42. 42.
    Ito Y, Kobayashi K, Tomoda C et al (2005) Ill-defined edge on ultrasonographic examination can be a marker of aggressive characteristic of papillary thyroid microcarcinoma. World J Surg 29:1007–1012CrossRefPubMedGoogle Scholar
  43. 43.
    Rodolico V, Cabibi D, Pizzolanti G et al (2007) BRAFV600E mutation and p27kip1 expression in papillary carcinoma of the thyroid ≤ 1 cm and their paired lymph node metastases. Cancer 110:1218–1226CrossRefPubMedGoogle Scholar
  44. 44.
    Lee X, Gao M, Ji Y et al (2009) Analysis of differential BRAFV600E mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 16:240–245CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2010

Authors and Affiliations

  • Iwao Sugitani
    • 1
  • Kazuhisa Toda
    • 1
  • Keiko Yamada
    • 2
  • Noriko Yamamoto
    • 3
  • Motoko Ikenaga
    • 4
  • Yoshihide Fujimoto
    • 1
  1. 1.Division of Head and NeckCancer Institute HospitalTokyoJapan
  2. 2.Department of UltrasonographyCancer Institute HospitalTokyoJapan
  3. 3.Department of PathologyCancer Institute HospitalTokyoJapan
  4. 4.Department of CytologyCancer Institute HospitalTokyoJapan

Personalised recommendations